Cefprozil is a cephalosporin antibiotic used in the treatment of various bacterial infections, such as pharyngitis, tonsillitis, otitis media, and uncomplicated skin infections. Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
- Mechanism
- Curator reviewed
Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor.
- Primary indication
- For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphCurator reviewed · 8 structured indications
- Formula / weight
- C18H19N3O5S · 389.426 g/mol (avg)
- First approval
- Canada, 2007 · United States, 2005
- Code names
- BBS-1067 · BMY-28167
Resolves to
WDLWHQDACQUCJR-PBFPGSCMSA-NSMILES[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Cefprozil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account